Source-grounded facts extracted from AN2 Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
AN2 Therapeutics, Inc. shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-03 meeting.
“2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions 22,724,674 13 16,848”
AN2 Therapeutics, Inc. shareholders approved Election of the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors at the 2026-06-03 meeting.
“1. To elect the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors until the Company’s 2029 annual meeting of stockholders or until their respective successors have been elected or appointed. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Kabeer Aziz 13,547,536 3,958,874 5,235,125 Gilbert Lynn Marks, M.D. 15,947,854 1,558,556 5,235,125 Rob Readnour, Ph.D. 15,920,563 1,585,847 5,235,125”
AN2 Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2025.
“On March 17, 2026, AN2 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter ended December 31, 2025.”
AN2 Therapeutics, Inc. issued 5,789,493 shares of Common Stock of warrant to certain investors for $2.84999 per Pre-Funded Warrant.
“of 5,789,493 shares of Common Stock (the “Pre-Funded Warrants,” and, together with the Shares, the “Securities”) (collectively, the “Private Placement”). The price per Share is $2.85, and the price per Pre-Funded Warrant is $2.84999. The closing of the Private Placement is expected to occur on March 10, 2026 (the “Closing”). The Pre-Funded Warrants have an”
AN2 Therapeutics, Inc. issued 8,245,611 shares of common stock to certain investors for $2.85 per share.
“of 5,789,493 shares of Common Stock (the “Pre-Funded Warrants,” and, together with the Shares, the “Securities”) (collectively, the “Private Placement”). The price per Share is $2.85, and the price per Pre-Funded Warrant is $2.84999. The closing of the Private Placement is expected to occur on March 10, 2026 (the “Closing”). The Pre-Funded Warrants have an”
AN2 Therapeutics, Inc. entered into Securities Purchase Agreement with certain investors valued at approximately $40 million (effective 2026-03-08).
“On March 8, 2026, AN2 Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”).”
Joshua Eizen was appointed as Chief Legal Officer and Chief Operating Officer at AN2 Therapeutics, Inc..
“On November 4, 2024, the Board of Directors of AN2 Therapeutics, Inc. (the “Company”) appointed Joshua Eizen, the Company’s current Chief Legal Counsel, age 47, as Chief Legal Officer and Chief Operating Officer of the Company, effective immediately”
AN2 Therapeutics, Inc. announced a restructuring with charges of approximately $2-$3 million (approximately 50% of the Company's employee workforce).
“On August 7, 2024, the Board of Directors of AN2 Therapeutics, Inc. (the “Company”) approved a reduction in force that is intended to result in the termination of approximately 50% of the Company’s employee workforce.”
Paul Eckburg departed as Chief Medical Officer at AN2 Therapeutics, Inc..
“Paul Eckburg, M.D., the Company’s Chief Medical Officer, will depart the Company effective as of August 30, 2024”
AN2 Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $16.6 million.
“AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024.”
AN2 Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2023 results: net income Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year. Net loss for the fourth.
“AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023.”
AN2 Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income Net loss was $16.7 million.
“On November 9, 2023, AN2 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023.”
Annie Yoshiyama was appointed as Vice President, Finance and Corporate Controller at AN2 Therapeutics, Inc..
“The Company has hired Annie Yoshiyama, previously Senior Vice President, Finance and Chief Accounting Officer at Tricida, Inc., as its new Vice President, Finance and Corporate Controller.”
Michael Nazak departed as Vice President, Corporate Controller at AN2 Therapeutics, Inc..
“Michael Nazak, Vice President, Corporate Controller and the prior Principal Accounting Officer, will depart the Company effective September 15, 2023.”
Lucy Day was appointed as Principal Accounting Officer at AN2 Therapeutics, Inc..
“On September 1, 2023, the Company’s Board of Directors appointed Lucy Day, the Company’s current Chief Financial Officer and Principal Financial Officer, to also serve as the Company’s Principal Accounting Officer effective as of September 1, 2023.”
AN2 Therapeutics, Inc. entered into Underwriting Agreement with Cowen and Company, LLC, Leerink Partners LLC and Evercore Group L.L.C., as representatives of the underwriters named in Schedule A therein valued at approximately $70.0 million (effective 2023-08-15).
“On August 15, 2023, AN2 Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC, Leerink Partners LLC and Evercore Group L.L.C., as representatives of the underwriters named in Schedule A therein (the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) by the Company of 7,777,778 shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), at an offering price of $9.00 per share.”
AN2 Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $15.8 million for the three months ended June 30, 2023.
“AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended June 30, 2023.”
AN2 Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2023. at the 2023-06-07 meeting.
“2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting results were as follows: Votes For Votes Against Abstentions Total 16,558,919 51,629 0 16,610,548”
AN2 Therapeutics, Inc. shareholders approved Election of three Class I directors: Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D. at the 2023-06-07 meeting.
“1. To elect the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors until the Company’s 2026 annual meeting of stockholders or until their respective successors have been elected or appointed. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Total Kabeer Aziz 14,783,208 747,428 1,079,912 16,610,548 Gilbert Lynn Marks, M.D. 14,781,503 749,133 1,079,912 16,610,548 Rob Readnour, Ph.D. 14,607,802 922,834 1,079,912 16,610,548”
AN2 Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income $15.3 million.
“Net loss was $15.3 million for the three months ended March 31, 2023, compared to $7.7 million in the prior year.”
AN2 Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income net loss was $11.8 million and $41.0 million, respectively.
“AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2022.”
AN2 Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.
“AN2 Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2022.”
Margaret (Maggie) M. FitzPatrick was appointed as Class II Director at AN2 Therapeutics, Inc..
“On May 5, 2022, Margaret (Maggie) M. FitzPatrick was appointed to the board of directors (the “ Board ”) of AN2 Therapeutics, Inc., a Delaware corporation (the “ Company ”), as a Class II Director”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.